Prescription medicine
Almotriptan First approved as Axert
Almotriptan (Axert) is a prescription medicine with an FDA approval on record since 2001. FDA's NDC Directory lists it from 3 generic labelers, and pharmacies paid $16.86 per almotriptan malate 12.5 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the almotriptan FDA label on DailyMed (effective December 31, 2025, Ajanta Pharma USA Inc.); the NDA 21001 record on Drugs@FDA; every almotriptan label on DailyMed.
Highlights of the record
FDA label of December 31, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageAlmotriptan tablets, USP are 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura ( 1.1 ) Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more ( 1.1 ) Important limitations: Use only after a cl
Forms and strengths
- 6.25 mg
- 12.5 mg
Film-coated tablet.
On the market
- Earliest approval on file
- May 7, 2001 Axert, Janssen Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 3 first July 7, 2015; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 3 of which 3 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $16.86 per tablet Almotriptan malate 12.5 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,008 through July 30, 2026
What is almotriptan used for?
From the label: indications and usageAlmotriptan tablets, USP are 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura ( 1.1 ) Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more ( 1.1 ) Important limitations: Use only after a clear diagnosis of migraine has been established ( 1.2 ) In adolescents age 12 to 17 years, efficacy of almotriptan tablets on migraine-associated symptoms was not established ( 1.2 ) Not intended for the prophylactic therapy of migraine ( 1.2 ) Not indicated for the treatment of cluster headache ( 1.2 ) 1.1 Acute Treatment of Migraine Attacks Adults Almotriptan tablets, USP are indicated for the acute treatment of migraine attacks in patients with a history of migraine with or without aura. […]
Conditions named in the indications of almotriptan's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Serotonin-1b and Serotonin-1d Receptor Agonist.
Source: FDA drug label (almotriptan), Ajanta Pharma USA Inc., effective December 31, 2025 (SPL set 6fa380c4-c885-4743-85bf-88819ae68645), via openFDA; the full label on DailyMed
Is there a generic for almotriptan (Axert)?
The FDA approved the first generic almotriptan on July 7, 2015. 3 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists almotriptan from 3 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2001 earliest approval on file
- 2015 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for almotriptan (Axert)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $16.86 per Almotriptan malate 12.5 mg tablet, down 9% from $18.53 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Almotriptan malate 6.25 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Almotriptan malate 12.5 mg tablet | Generic | $16.86 per tablet | $505.70 | -9% |
| Almotriptan malate 6.25 mg tablet | Generic | $16.51 per tablet | $495.27 | -21% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the almotriptan label say about other medicines?
The almotriptan label names 11 other medicines in its interaction, contraindication or warning sections. The labels of 1 other medicine name almotriptan. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Citalopram | warnings and precautions | If concomitant treatment with almotriptan tablets and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. |
| Dihydroergotamine | contraindications | Do not use almotriptan tablets and ergotamine-containing or ergot-derived medications like dihydroergotamine, ergotamine tartrate, or methysergide within 24 hours of each other [see Drug Interactions ( 7.1 )]. |
| Duloxetine | warnings and precautions | If concomitant treatment with almotriptan tablets and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. |
| Ergotamine | contraindications | Do not use almotriptan tablets and ergotamine-containing or ergot-derived medications like dihydroergotamine, ergotamine tartrate, or methysergide within 24 hours of each other [see Drug Interactions ( 7.1 )]. |
| Escitalopram | warnings and precautions | If concomitant treatment with almotriptan tablets and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. |
| Fluoxetine | warnings and precautions | If concomitant treatment with almotriptan tablets and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. |
| Fluvoxamine | warnings and precautions | If concomitant treatment with almotriptan tablets and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. |
| Ketoconazole | drug interactions | … SSRI or SNRI: life-threatening serotonin syndrome reported during combined use with triptans ( 5.5 , 7.3 ) Ketoconazole: use single dose of almotriptan tablets 6.25 mg; maximum almotriptan tablets daily dose 12.5 mg |
| Paroxetine | warnings and precautions | If concomitant treatment with almotriptan tablets and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. |
| Sertraline | warnings and precautions | If concomitant treatment with almotriptan tablets and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. |
| Venlafaxine | warnings and precautions | If concomitant treatment with almotriptan tablets and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. |
Other labels that name almotriptan
Source: FDA drug label (almotriptan), Ajanta Pharma USA Inc., effective December 31, 2025 (SPL set 6fa380c4-c885-4743-85bf-88819ae68645), via openFDA; the full label on DailyMed
What do FAERS reports show for almotriptan?
The FDA Adverse Event Reporting System holds 1,008 reports that list almotriptan among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 48 are coded as a death and 210 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as almotriptan?
13 other medicines are given the same way (oral) and in the same FDA class as almotriptan or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Sumatriptan | Migraine | 22 labelers | $0.302 per tablet 50 mg tablet | No current entry |
| Rizatriptan | Migraine | 25 labelers | $0.335 per tablet 10 mg tablet | No current entry |
| Zolmitriptan | Migraine | 18 labelers | $1.02 per tablet 2.5 mg tablet | No current entry |
| Eletriptan | Migraine | 10 labelers | $1.75 per tablet 40 mg tablet | No current entry |
| Naratriptan | Migraine | 4 labelers | $1.08 per tablet 2.5 mg tablet | No current entry |
| Naproxen and sumatriptan | Migraine | 3 labelers | $10.46 per unit 85-500 mg | No current entry |
| Frovatriptan | Migraine | 4 labelers | $2.72 per tablet 2.5 mg tablet | A presentation being discontinued |
| Meloxicam and rizatriptan | Migraine | none listed | $122.64 per tablet 20-10 mg tablet | No current entry |
Every medicine labeled for the same conditions as almotriptan
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to almotriptan
- 13 medicines for the same use
- Other triptans
- the pharmacologic class, with prices and generics
- Almotriptan side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other